SCHEMBL672388

SCHEMBL672388

NC(=O)c1cc(COc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 8/20 0.74
KDR P35968 7/20 0.59
BRAF P15056 3/20 0.58
CDK8 P49336 2/20 0.58
CA7 P43166 2/20 0.58
CA9 Q16790 2/20 0.58
GSK3B P49841 2/20 0.58
MAPK14 Q16539 2/20 0.58
MEN1 O00255 1/20 0.58
PLK4 O00444 1/20 0.58
CIT O14578 1/20 0.58
AURKA O14965 1/20 0.58
MUSK O15146 1/20 0.58
EPHB6 O15197 1/20 0.58
MAPK13 O15264 1/20 0.58
MLNR O43193 1/20 0.58
MAP3K7 O43318 1/20 0.58
RIPK2 O43353 1/20 0.58
DYRK3 O43781 1/20 0.58
PDE6D O43924 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21955644 0.90 RAF1 (0.64) RAF1KDRBRAFCDK8CA7
Water SCHEMBL3841018 0.90 RAF1 (0.63) RAF1KDRBRAFCDK8CA7
SCHEMBL29918250 0.85 RAF1 (1.00) RAF1KDRBRAFCDK8CA7
SCHEMBL548133 0.85 RAF1 (1.00) RAF1KDRBRAFCDK8CA7
SCHEMBL16621032 0.83 RAF1 (0.52) RAF1MEN1AURKARPS6KB1KMT2A
SCHEMBL3790500 0.81 KDR (0.64) RAF1KDRBRAFCDK8CA7
SCHEMBL3766220 0.81 RAF1 (0.48) RAF1KDRBRAF
SCHEMBL4238109 0.80 RAF1 (0.82) RAF1KDRBRAFCDK8CA7
SCHEMBL171199 0.80 RAF1 (0.81) RAF1KDRBRAFCDK8CA7
SCHEMBL939087 0.80 RAF1 (0.85) RAF1KDRBRAFCDK8CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2632458-A1 DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE Novartis AG (CH) 2013-09-04 EP disclosed
EP-2605650-A2 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL Del Mar Pharmaceuticals (CA) 2013-06-26 EP disclosed
WO-2012055884-A1 DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE NOVARTIS AG (CH) 2012-05-03 WO disclosed
WO-2012024367-A2 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL DEL MAR PHARMACEUTICALS (CA) 2012-02-23 WO disclosed